Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

NCT ID: NCT05726110

Last Updated: 2024-10-22

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-29
• Study Completion Date: 2024-12-31

Brief Summary

This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

Detailed Description

Main Purpose：

To observe the efficacy of selinexor in combination with HAD or CAG regimen for relapsed and refractory acute myeloid leukemia :complete remission rate (CR rate), partial remission rate (PR rate), no remission rate (NR rate), complete remission with incomplete hematologic recovery(CRi rate)

Secondary Purposes：

1. To observe the recurrence rate of selinexor combined with HAD or CAG regimen for relapsed and refractory acute myeloid leukemia, treatment-related mortality(TRM), Overall Survival (OS), Event-Free Survival (EFS);

2. Safety indicators: to observe adverse events and deaths during treatment with selinexor in combination with HAD or CAG regimen.

Conditions

Relapsed or Refractory Acute Myeloid Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Selinexor、HAD or CAG regimens

• Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.
• (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m^2/d)×7days, daunorubicin (DNR, 40mg/ m^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process)；
• (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).
• G-CSF was discontinued in the CAG regimen when WBC > 20×10^9/L, but chemotherapy was not stopped.

Group Type: EXPERIMENTAL

Selinexor

Intervention Type: DRUG

Given PO

Homoharringtonine

Intervention Type: DRUG

Given per standard of care

Daunorubicin

Intervention Type: DRUG

Given per standard of care

Cytarabine

Intervention Type: DRUG

Given per standard of care

Granulocyte Colony-Stimulating Factor

Intervention Type: DRUG

Given per standard of care

Aclacinomycin

Intervention Type: DRUG

Given per standard of care

Interventions

Selinexor

Given PO

Intervention Type: DRUG

Homoharringtonine

Given per standard of care

Intervention Type: DRUG

Daunorubicin

Given per standard of care

Intervention Type: DRUG

Cytarabine

Given per standard of care

Intervention Type: DRUG

Granulocyte Colony-Stimulating Factor

Given per standard of care

Intervention Type: DRUG

Aclacinomycin

Given per standard of care

Intervention Type: DRUG

Other Intervention Names

KPT-330; HHT; DNR; Ara-C; G-CSF; ACM

Eligibility Criteria

Inclusion Criteria

1. Age:18-60 years old;

2. Except for patients with AML-M3 with acute myeloid leukemia；

3. Meet the diagnostic criteria for refractory AML (2011 Chinese guidelines for the diagnosis and treatment of acute myeloid leukemia (relapsed or refractory)):(1) The standard regimen did not achieve complete remission after 2 courses of induction chemotherapy;(2) Relapse within 6 months after the first complete remission; (3) Patients who relapse after 6 months after the first complete remission, and those who fail to induce chemotherapy after the original program; (4) 2 or more recurrences; (5) Extramedullary leukemia persists；

4. Meet the diagnostic criteria for recurrent AML (refer to the 2014 NCCN guidelines): after complete remission, (1) naive cells appear in peripheral blood; (2) >5% of bone marrow naive cells; (3) Extramedullary recurrence；

5. The bone marrow image indicates active hyperplasia or hypoproliferation；

6. Eastern Oncology Collaborative Group Physical Status Assessment (ECOG-PS) with a score of 0-2.

Exclusion Criteria

1. Accompanied by cerebral hemorrhage；

2. Pregnancy；

3. Have a mental illness or other condition that cannot proceed as planned；

4. Severe arrhythmia, abnormal ECG (QT>500ms).

Early withdrawal from test criteria：

Participants have the right to withdraw from the study at any time from the trial. Exit Criteria:

1. The subject or the subject's legally authorized representative requests to withdraw from the study;

2. Participant loss to follow-up.

Doctor/Investigator required subjects to terminate the trial early:

1. Subjects who are unable to carry out follow-up treatment due to adverse events (serious irreversible organ function damage during treatment) who are judged by the investigator to be unsuitable for continuing the research;

2. The subject does not adhere to the protocol, such as the use of chemotherapy drugs, etc., which affects the effectiveness and safety judgment.

For participants who withdrew early from the study (except subjects who were lost to follow-up), the reason for their early withdrawal should be recorded, and the time of the last study's medication/treatment should be recorded, and the examination items at the time of early withdrawal from the study should be completed at the last visit, if possible.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Antengene Corporation

INDUSTRY

Sponsor Role: collaborator

Shanxi Bethune Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tao Wang

Role: STUDY_DIRECTOR

Shanxi Bethune Hospital Regulatory Authority

Locations

Tao Wang

Taiyuan, Shanxi, China

Site Status: RECRUITING

Countries

China

Central Contacts

Tao Wang

Role: CONTACT

wangtao99699@163.com

13835175119

Facility Contacts

Tao Wang, doctorial

Role: primary

wangtao99699@163.com

13835175119

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

ShanxiBethuneH

Identifier Type: -

Identifier Source: org_study_id